(Albany, US) DelveInsight launched a new report on “Dry Eye Disease (DED) Market Insights, Epidemiology and Market Forecast-2030”.
DelveInsight’s “Dry Eye Disease (DED) Market Insights, Epidemiology and Market Forecast-2028″ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of DED in EU5 (Germany, Spain, Italy, France and United Kingdom).
Some of the facts of the report
1. As per DelveInsight estimates, market size for EU5 was USD 602.62 million in 2017.
2. As per DelveInsight analysis, it is observed that, Germany had the highest prevalent population of Dry Eye Disease in EU5.
3. DelveInsight’s Analysis, it can be observed that Dry Eye Disease cases among the age group 46–65 years are far higher in number than other age groups. It can also be observed that patients below 17 years are least prone to DED.
4. As per Delveinsight’s estimates, the total prevalent population of Dry Eye Disease in EU5 was 11,939,169 in 2017
Key benefits of the report
1. Dry Eye Disease market report covers a descriptive overview and comprehensive insight of the Dry Eye Disease epidemiology and Dry Eye Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Dry Eye Disease market report provides insights on the current and emerging therapies.
3. Dry Eye Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. Dry Eye Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Dry Eye Disease market.
Request for sample pages : https://www.delveinsight.com/sample-request/dry-eye-disease-market
“ Among the Dry Eye Disease patients, Females accounts for a higher number of Dry Eye Disease cases than Males in 7MM.”
Dry Eye Disease, also known as Dry Eye Syndrome (DES) or Keratoconjunctivitis Sicca, is a common condition when eyes do not produce enough tears or the tears evaporate too quickly, that is essential to lubricate and nourish the eye. The condition leads to eyes drying out and becoming red, swollen, and irritated. Causes for DES include decreased tear production, excessive tear evaporation, and abnormality in the production of mucus or lipids of tear layer.
The disease management basically aims to relieve the discomfort and prevent the damage to the cornea, at the front of the eye. The currently available treatment options for Dry Eye Disease depend on the severity of the condition and may include medication, surgery, and others (eyelid therapy (warm compresses and eyelid hygiene, contact lenses, and moisture chamber spectacles)).
The main symptom of dry eyes is dry and gritty feeling in the eyes. The additional symptoms include burning or itching in the eyes, foreign body sensation, excess tearing, pain and redness of the eyes, and photophobia in some cases. Sometimes, it is also associated with a stringy discharge and blurred, changing vision. Symptoms are found to worsen in dry weathers, with low humidity and higher temperatures.
“ According to DelveInsight’s analysis, mild cases of Dry Eye Disease are more prominent in comparison to moderate and severe cases “
The launch of the emerging therapies is expected to significantly impact Dry Eye Disease treatment scenario in the upcoming years:-
Drugs covered
- OC‐01/OC‐02
- OCU 310
- HMB9036
- Visomitin
- RGN‐295
- Travilermide ophthalmic solution
- KPI‐121
And many others
The key players in Dry Eye Disease market are:
- Oyster Point Pharma
- Ocugen
- HanAI Biopharma
- Mitotech Pharma
- ReGen Tree
- Mimetogen Pharmaceuticals
- Kala Pharmaceuticals
And many others
Request for sample pages : https://www.delveinsight.com/sample-request/dry-eye-disease-market
Table of contents
Dry Eye Disease Market Overview at a Glance
Market Share (%) Distribution of Dry Eye Disease in 2017
Market Share (%) Distribution of Dry Eye Disease in 2030
Disease Background and Overview
Introduction
Historical overview of dry eye
Classification schemes for dry eye disease
Etiology and risk factors
Causes
Signs and Symptoms
Pathology of Dry Eye Disease
Diagnosis
Epidemiology and Patient Population – EU5 Markets
Key Findings
KOL’s Views: Epidemiology
EU5 Total Prevalent Patient Population of Dry Eye Disease
Country Wise‐Epidemiology of Dry Eye Disease
The United States
EU5
Assumptions and Rationale
Germany
France
Italy
Spain
The United Kingdom
Japan
Treatment and Management of Dry Eye Disease
Unmet Needs
Marketed Drugs
IKERVIS: Santen Pharmaceutical
Product Description
Regulatory Milestones
Safety and Efficacy
Product Profile
Emerging Therapies
Visomitin: Mitotech pharma
Product Description
Other development Activities
Clinical Development
Safety and Efficacy
Advantages and Disadvantages
Product Profile
RGN‐259: ReGen Tree
Product Description
Other development Activities
Clinical Development
Safety and Efficacy
Advantages and Disadvantages
Product Profile
HBM9036: HanAll BioPharma/ Harbour BioMed
Product Description
Other development Activities
Clinical Development
Safety and Efficacy
Advantages and Disadvantages
Product Profile
NOV03: Novaliq
Product Description
Other development Activities
Clinical Development
Safety and Efficacy
Advantages and Disadvantages
Product Profile
OCU310: Ocugen
Product Description
Other development Activities
Clinical Development
Safety and Efficacy
Advantages and Disadvantages
Product Profile
KPI‐121: Kala Pharmaceuticals
Product Description
Other development Activities
Clinical Development
Safety and Efficacy
Advantages and Disadvantages
Product Profile
CyclASol: Novaliq
Product Description
Other Development Activities
Clinical Development
Safety and Efficacy
Advantages and Disadvantages
Product Profile
CEQUA: Sun Pharma
Product Description
Clinical Development
Safety and Efficacy
Advantages and Disadvantages
Product Profile
Tivanisiran: Sylentis, S.A.
Product Description
Other Development Activity
Clinical Development
Safety and Efficacy
Advantages and Disadvantages
Product Profile
Reproxalap: Aldeyra Therapeutics
Product Description
Clinical Development
Safety and Efficacy
Advantages and Disadvantages
Product Profile
Xiidra: Novartis
Product Description
Other Development Activity
Clinical Development
Safety and Efficacy
Advantages and Disadvantages
Product Profile
Dry Eye Disease: EU‐5 Market Analysis
Key Findings
KOL’s Views: Treatment & Diagnosis
Market Size of Dry Eye Disease in 7MM
Market Size of Dry Eye Disease by Therapies
Market size of Dry Eye Disease by Types
Market Outlook by Country
United States: Market Outlook
Total Market size of Dry Eye Disease
Market Size of Dry Eye Disease by Therapies
Total Market size of Dry Eye Disease by Types
EU ‐ 5 Countries: Market Outlook
Germany
Total Market size of Dry Eye Disease
Market Size of Dry Eye Disease by Therapies
Total Market size of Dry Eye Disease by Types
France
Total Market size of Dry Eye Disease
Market Size of Dry Eye Disease by Therapies
Total Market size of Dry Eye Disease by Types
Italy
Total Market size of Dry Eye Disease
Market Size of Dry Eye Disease by Therapies
Total Market size of Dry Eye Disease by Types
Spain
Total Market size of Dry Eye Disease
Market Size of Dry Eye Disease by Therapies
Total Market size of Dry Eye Disease by Types
United Kingdom
Total Market size of Dry Eye Disease
Market Size of Dry Eye Disease by Therapies
Total Market size of Dry Eye Disease by Types
Japan: Market Outlook
Total Market size of Dry Eye Disease
Market Size of Dry Eye Disease by Therapies
Total Market size of Dry Eye Disease by Types
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
Related Reports:
Dry eye disease – Pipeline Insights, 2020
The Dry eye disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Dry eye disease across the complete product development cycle, including all clinical and nonclinical stages.
Dry eye disease – Epidemiology Forecast to 2030
The Dry eye disease epidemiology covered in the report provides historical as well as forecasted Dry eye disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/